Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-021840
Filing Date
2022-11-03
Accepted
2022-11-03 16:05:16
Documents
61
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q fate-20220930.htm   iXBRL 10-Q 3571531
2 EX-31.1 fate-ex31_1.htm EX-31.1 16011
3 EX-31.2 fate-ex31_2.htm EX-31.2 16123
4 EX-32.1 fate-ex32_1.htm EX-32.1 11389
  Complete submission text file 0000950170-22-021840.txt   14664023

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fate-20220930.xsd EX-101.SCH 64492
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fate-20220930_pre.xml EX-101.PRE 401027
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT fate-20220930_cal.xml EX-101.CAL 47770
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fate-20220930_lab.xml EX-101.LAB 515144
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT fate-20220930_def.xml EX-101.DEF 271178
55 EXTRACTED XBRL INSTANCE DOCUMENT fate-20220930_htm.xml XML 3941635
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

EIN.: 651311552 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36076 | Film No.: 221357893
SIC: 2836 Biological Products, (No Diagnostic Substances)